Structure of disodium dihydrogen 1-hydroxyethylidenediphosphonate tetrahydrate: a bone growth regulator

Barnett, B.L.; Strickland, L. C.

doi:10.1107/s0567740879005938

Cited by 51 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This observation is supported by a number of X-ray data for HEDPA complexes [79BS,89SP,89SZ]. For example, sodium exhibits the ability to form chelate rings including the coordination of the aliphatic hydroxy-group even with the triply protonated ligand NaH 3 hedpa⋅H 2 O [90SM].…”

Section: Phosphonic Acid (Amph); [(Phosphonomethyl)-amino]acetic Acidmentioning

confidence: 75%

Critical evaluation of stability constants of phosphonic acids (IUPAC Technical Report)

Popov

Rönkkömäki

Lajunen

2001

Pure and Applied Chemistry

245

165

View full text Add to dashboard Cite

show abstract

Section: Phosphonic Acid (Amph); [(Phosphonomethyl)-amino]acetic Acidmentioning

confidence: 75%

Critical evaluation of stability constants of phosphonic acids (IUPAC Technical Report)

Popov

Rönkkömäki

Lajunen

2001

Pure and Applied Chemistry

245

165

View full text Add to dashboard Cite

show abstract

“…13,16 By contrast, the bone half-life is very long, from months to years in humans, because of the high affinity of these drugs for solid-phase calcium phosphate, resulting in binding to hydroxyapatite and accumulation in bone. 9,17 Bisphosphonates become trapped in the bone and are only released when the bone is resorbed. Approximately 50% of the absorbed drug is located in the bone.…”

Section: Pharmacokineticsmentioning

confidence: 99%

A systematic review of the role of bisphosphonates in metastatic disease

Ross

Saunders²,

Edmonds³

et al. 2004

Health Technol Assess

257

110

View full text Add to dashboard Cite

High dose aminobisphosphonates are most effective for the treatment of acute hypercalcaemia and delay time to relapse. Bisphosphonates significantly reduce SREs and delay the time to first SRE in patients with bony metastatic disease but do not affect survival. Benefit is demonstrated after administration for at least 6-12 months. The greatest body of evidence supports the use of intravenous aminobisphosphonates. Further evidence is required to support use in the adjuvant setting.

show abstract

“…The binding can be of two types (138,139): bidentate or tridentate. In bidentate binding, an oxygen atom from each phosphonate group binds onto a calcium of the hydroxyapatite.…”

Section: A Calcificationmentioning

confidence: 99%